An evaluation of avutometinib in combination with defactinib for KRAS-mutated recurrent low-grade serous ovarian cancer.

doi:10.1080/14737140.2026.2665840

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

An evaluation of avutometinib in combination with defactinib for KRAS-mutated recurrent low-grade serous ovarian cancer.

Expert review of anticancer therapy - 1 Sept 2026

Podder Vivek, Slomovitz Brian M, Coleman Robert L

Abstract excerpt

INTRODUCTION: Low-grade serous ovarian cancer (LGSOC) is a rare, biologically distinct subtype of epithelial ovarian cancer characterized by relative genomic stability, frequent activation of the mitogen-activated protein kinase (MAPK) pathway, and limited sensitivity to cytotoxic chemotherapy. Activating alterations in KRAS, NRAS, and BRAF mutations occur in 70% of cases, with KRAS being the predominant driver...

Read the complete abstract on PubMed

Topics

Humans
Female
Ovarian Neoplasms
Mutation
Antineoplastic Combined Chemotherapy Protocols
Proto-Oncogene Proteins p21(ras)

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Animals

Neoplasm Recurrence, Local

Benzamides

Carcinoma, Ovarian Epithelial

Diphenylamine

Pyrazines

Sulfonamides

Source

Open in PubMed

Identifiers

PMID: 42059499
DOI: 10.1080/14737140.2026.2665840

Genes

KRAS
BRAF
NRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 25 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

An evaluation of avutometinib in combination with defactinib for KRAS-mutated recurrent low-grade serous ovarian cancer.PMID 42059499Read ↗

Avutometinib and defactinib: a novel dual pathway inhibition strategy for recurrent KRAS-mutant low-grade serous ovarian cancer.Semantic proximity Read ↗

Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201.Semantic proximity Read ↗

Avutometinib and Defactinib: First Approval.Semantic proximity Read ↗

Co-targeting the PI3K-Akt pathway improves response to MEK inhibition in low-grade serous ovarian cancer cell linesSemantic proximity Read ↗

The RAS-MEK-ERK pathway in low-grade serous ovarian cancer.Semantic proximity Read ↗

Impressive and durable clinical responses obtained with dabrafenib and trametinib in low-grade serous ovarian cancer harbouring a BRAF V600E mutationSemantic proximity Read ↗

Molecular Profiling and Tumor Biomarker Analysis of GOG281/LOGS: A Positive Late-Phase Trial of Trametinib for Recurrent/Persistent Low-Grade Serous Ovarian Carcinoma.Semantic proximity Read ↗

Sustained response to vemurafenib in a low grade serous ovarian cancer with a BRAF V600E mutation.Semantic proximity Read ↗

Low grade serous ovarian cancer - A rare disease with increasing therapeutic options.Semantic proximity Read ↗

High throughput screening identifies dasatinib as synergistic with trametinib in low grade serous ovarian carcinomaSemantic proximity Read ↗

Differential Preclinical Efficacy of Combined CDK4/6 and MEK Inhibition in Low-Grade Serous Ovarian Carcinoma Based on KRAS/NF1 Mutational Status.Semantic proximity Read ↗

Low Grade Serous Ovarian Carcinoma: from the molecular characterization to the best therapeutic strategy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.